Related Experiment Video

Updated: Mar 31, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.4K

[Pneumococcal vaccines. New conjugate vaccines for adults]

Magda Campins Martí1

  • 1Servicio de Medicina Preventiva y Epidemiología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.

Enfermedades Infecciosas Y Microbiologia Clinica
|October 18, 2015
PubMed

Insights

Pneumococcal infections cause significant global deaths, especially in young children and older adults. New conjugate vaccines offer improved prevention strategies for pneumococcal disease compared to older vaccines.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Vaccinology

Background:

  • Pneumococcal infections represent a major global health burden, contributing significantly to morbidity and mortality.
  • Incidence is highest in children under 2 and adults over 64, with increased risk for immunocompromised individuals and asplenic patients.

Purpose of the Study:

  • To review the progress in pneumococcal infection prevention over the last decade.
  • To evaluate the shift from older non-conjugate vaccines to newer conjugate vaccines for adults.

Main Methods:

  • Literature review of pneumococcal infection epidemiology and vaccine development.
  • Comparative analysis of the efficacy and immune response of 23-valent non-conjugate and 13-valent conjugate pneumococcal vaccines.

Main Results:

  • Older 23-valent non-conjugate vaccines had controversial efficacy and limited immune response.
  • The introduction of the 13-valent conjugate vaccine in adults shows promise for enhanced prevention.

Conclusions:

  • Significant advancements in pneumococcal vaccine technology have been made.
  • The 13-valent conjugate vaccine offers improved prospects for preventing pneumococcal disease in adult populations.

Keywords:
AdultosAdultsPneumococcal vaccinesSteptococcus pneumoniaeStreptococcus pneumoniaeVacunas antineumocócicas

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.7K
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.5K

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.1K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
38